Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ZANACC: Phase 2 Non-randomized Single Arm Study Evaluating Zanzalintinib in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck

NCT07682675 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT07682675
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07682675 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ZANACC: Phase 2 Non-randomized Single Arm Study Evaluating Zanzalintinib in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
April 30, 2032
Enrollment
51 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adenoid cystic carcinoma of the salivary gland, metastatic disease, recurrence